Literature DB >> 20694530

Chronic kidney disease and albuminuria in arterial hypertension.

Giovanna Leoncini1, Francesca Viazzi, Roberto Pontremoli.   

Abstract

Chronic kidney disease is a major public health problem worldwide: it is estimated that in the general population, 1 person in 10 has some degree of renal damage. Adequate blood pressure control represents the mainstay of treatment, to delay deterioration of renal function and prevent cardiovascular complications. Current evidence supports a target blood pressure value of 130/80 mm Hg or less (ie, <125/75 mm Hg) when proteinuria exceeds 1 g/L. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers represent the treatment of choice, especially in the presence of proteinuria. More complete blockade of the renin-angiotensin-aldosterone system (RAAS) has been advocated, using a combination of multiple RAAS blocker drugs or supramaximal doses to maximize renal protection. Achieving recommended blood pressure target values usually requires the use of multiple antihypertensive drugs, including diuretics and calcium channel blockers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694530     DOI: 10.1007/s11906-010-0141-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  46 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors: 
Journal:  Lancet       Date:  2009-10-10       Impact factor: 79.321

3.  Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus.

Authors:  J Wagner; F Gehlen; A Ciechanowicz; E Ritz
Journal:  J Am Soc Nephrol       Date:  1999-03       Impact factor: 10.121

4.  Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan.

Authors:  Kunitoshi Iseki; Kozen Kinjo; Chiho Iseki; Shuichi Takishita
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

5.  Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

Authors:  Norman K Hollenberg; Hans-Henrik Parving; Giancarlo Viberti; Giuseppe Remuzzi; Susan Ritter; Steven Zelenkofske; Albert Kandra; William L Daley; Ricardo Rocha
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

6.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

7.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Mathieu Ghadanfar; Nicole Weissbach; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer
Journal:  Nephrol Dial Transplant       Date:  2009-01-14       Impact factor: 5.992

8.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

9.  Lowering blood pressure reduces renal events in type 2 diabetes.

Authors:  Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

Review 10.  Renin-angiotensin system revisited.

Authors:  F Fyhrquist; O Saijonmaa
Journal:  J Intern Med       Date:  2008-09       Impact factor: 8.989

View more
  4 in total

1.  Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage.

Authors:  Weiru Zhang; Wei Wang; Hong Yu; Yujin Zhang; Yingbo Dai; Chen Ning; Lijian Tao; Hong Sun; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  Hypertension       Date:  2011-11-07       Impact factor: 10.190

2.  Prognostic impact of baseline urinary albumin excretion rate in patients with resistant hypertension: a prospective cohort study.

Authors:  Paula Moreira da Costa; Arthur Fernandes Cortez; Fabio de Souza; Gabriel de Souza Mares; Bruno Dussoni Moreira Dos Santos; Elizabeth Silaid Muxfeldt
Journal:  J Hum Hypertens       Date:  2017-12-11       Impact factor: 3.012

3.  High resolution molecular and histological analysis of renal disease progression in ZSF1 fa/faCP rats, a model of type 2 diabetic nephropathy.

Authors:  Ken Dower; Shanrong Zhao; Franklin J Schlerman; Leigh Savary; Gabriela Campanholle; Bryce G Johnson; Li Xi; Vuong Nguyen; Yutian Zhan; Matthew P Lech; Ju Wang; Qing Nie; Morten A Karsdal; Federica Genovese; Germaine Boucher; Thomas P Brown; Baohong Zhang; Bruce L Homer; Robert V Martinez
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

Review 4.  Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.

Authors:  Francesca Viazzi; Giovanna Leoncini; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.